Search

Researchers at Abou Bekr Belkaid University conducted a study on the potential interaction between levothyroxine sodium and thyme (Thymus vulgaris) in thyroid drugs. The study focused on a case report of a 52-year-old woman who experienced palpitations after consuming T. vulgaris tea while on levothyroxine therapy for hypothyroidism. The researchers concluded that there is a probable interaction between levothyroxine sodium and thyme, highlighting the importance of caution when using herbal remedies alongside conventional treatments for thyroid disorders. The study was published in the Journal of Pharmacy & Pharmacognosy Research and can be accessed for further information. [Extracted from the article]

Recent research from the University of Illinois highlights the potential impact of GLP-1 RA therapy on thyroid stimulating hormone levels in post-thyroidectomy patients. A case study revealed suppressed TSH levels in a patient after starting subcutaneous semaglutide, leading to a dose reduction of levothyroxine. The study suggests the need for closer monitoring of patients on GLP-1 RA therapy and further research in this area to better understand the effects on thyroid function. [Extracted from the article]

Researchers at Mustansiriyah University conducted a study in Karbala City to estimate the prevalence of primary hypothyroidism and its clinical manifestations among patients receiving levothyroxine therapy. The study found that levothyroxine treatment improved symptoms such as sluggish speech, constipation, lack of appetite, cold sensitivity, weight gain, and weariness. The research concluded that there was no observed correlation between the dosage of levothyroxine and the manifestation of signs and symptoms. The study was published in the Al-Mustansiriyah Journal of Pharmaceutical Sciences in 2024. [Extracted from the article]

A study from Jiangsu, China, explored the link between subclinical hypothyroidism (SCH) and adverse pregnancy outcomes, as well as the effects of levothyroxine (LT4) therapy on maternal and infant prognosis. The research found that SCH during pregnancy increased the risk of hypertensive disease, fetal growth restriction, premature delivery, and fetal death. However, LT4 replacement therapy was shown to improve outcomes for both mothers and infants, regardless of thyroid peroxidase antibody (TPOAb) status. The study involved 635 pregnant women with SCH and 1876 women with normal thyroid function as a control group. [Extracted from the article]

The article discusses a clinical trial, NCT06660823, focusing on the role of levothyroxine supplementation in aiding delayed recovery post cardiac surgery. Hypothyroidism has been linked to various cardiovascular and respiratory complications, affecting heart function and recovery. The study aims to investigate the effects of oral levothyroxine supplementation on patients experiencing delayed recovery after cardiac surgery, with a focus on improving physical fitness and heart function. The trial is set to enroll adult patients aged 45-70 years in Egypt, with a primary completion date of May 31, 2025. [Extracted from the article]

A patent application titled "Preparation Of P2x3 Antagonist" was published online by inventors KRONENTHAL, David R. and VILLENEUVE, Karine. The application describes processes for the synthesis of P2X3 antagonists, specifically focusing on a compound known as methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate. The application details various methods and reactions involved in the preparation of this compound. The patent application was filed on August 16, 2022, and made available online on October 24, 2024. [Extracted from the article]

A recent study conducted at Semmelweis University analyzed factors influencing the dose of levothyroxine treatment in patients with hypothyroidism of different etiologies. The study found that patients with autoimmune hypothyroidism required significantly lower doses of levothyroxine compared to those with post-surgery hypothyroidism. Factors such as age, body weight, BMI, and time since diagnosis were identified as significant predictors of levothyroxine requirement in patients with autoimmune hypothyroidism. The research highlights the importance of considering the underlying cause of hypothyroidism when determining levothyroxine replacement therapy. [Extracted from the article]

A recent study conducted at Zuyderland Medical Center focused on patient experiences and preferences regarding the recommended fasting administration of levothyroxine (LT4) for thyroid treatment. The research found that while 97.3% of patients received instructions to fast before taking LT4, only 30% adhered to this recommendation. Many patients expressed a preference for non-fasting LT4 ingestion due to the burden of postponing breakfast, leading to irregular intake and even medication omission. The study suggests further research into alternative non-fasting administration methods to improve adherence and patient satisfaction. [Extracted from the article]

A recent study from Cardiff University delves into the complexities of hypothyroidism, a common condition globally that affects various body systems and can present with a range of symptoms. The research highlights the importance of individualized reference intervals for thyroid function tests and discusses the standard treatment of levothyroxine therapy. The study also addresses ongoing debates surrounding treatment thresholds and strategies for managing hypothyroidism, providing valuable insights for future research in this field. [Extracted from the article]

Researchers from a Cancer Hospital in Faisalabad, Pakistan, conducted a study on the rapid absorption of levothyroxine to assess nonadherence to treatment in six patients with persistent hypothyroidism. The study found that a 2-hour levothyroxine absorption test could be a more convenient method to differentiate nonadherence from malabsorption. The research concluded that scheduling patients for testing may result in improved adherence to levothyroxine therapy. The study was published in the European Journal of Medical Case Reports in 2024. [Extracted from the article]

A recent study conducted at Tanta University focused on the histopathological effects of chronic levothyroxine sodium administration on the gastric mucosa of adult male albino rats. The study found that long-term oral levothyroxine sodium treatment led to harmful structural changes in the gastric mucosa of the rats. This research sheds light on the potential deleterious effects of this commonly used thyroid drug on the stomach lining. For more information, the full article can be accessed in the Journal of Microscopy and Ultrastructure. [Extracted from the article]

A recent study conducted at the King Faisal Specialist Hospital and Research Centre compared two different approaches for administering levothyroxine to thyroidectomized patients during Ramadan fasting. The study found that increasing the pre-Ramadan dose of levothyroxine by 25-50 mcg and eating immediately may be a preferable approach, especially for patients who need TSH suppression. The research concluded that no overt thyroid dysfunction developed, but there were more cases of subclinical hypothyroidism in one group and subclinical hyperthyroidism in the other. The findings suggest that this approach may help achieve desirable levels of TSH in a majority of cases. [Extracted from the article]

A recent study conducted at the University of Miami focused on the combined use of propylthiouracil (PTU) and levothyroxine (LT4) in treating monocarboxylate transporter 8 (MCT8) deficiency in 12 male patients. The research aimed to identify optimal therapeutic dosages and evaluate treatment safety and outcomes. Results showed that the combined treatment effectively normalized serum thyroid hormone levels in patients with MCT8 deficiency, emphasizing the importance of individualized dose adjustments for personalized treatment plans. The study was funded by the National Institutes of Health (NIH) and the Esformes Thyroid Research Fund, and has been peer-reviewed for publication in Thyroid. [Extracted from the article]

A study conducted at Bashkir State Medical University in Ufa, Russia, compared the effects of low-iodine diet and methimazole-induced hypothyroidism on oxidative metabolism in the liver of rats. The research found that the low-iodine diet model led to more significant inhibition of thyroid function compared to the methimazole-induced hypothyroidism model. The results suggest that conflicting data on oxidative metabolism in hypothyroidism may be due to different approaches used to model thyroid dysfunction. For more information, the study was published in the Biomedical and Pharmacology Journal. [Extracted from the article]

A recent study conducted by researchers at the Central Arkansas Veterans Healthcare System aimed to determine the frequency and determinants of levothyroxine therapy initiation for veterans with subclinical hypothyroidism (SCH). The study found that 27.5% of veterans with SCH were treated with levothyroxine. Factors associated with higher odds of treatment included being White and having a higher thyrotropin level. The study suggests potential disparities and the influence of SCH severity on treatment decision-making. Further research is needed to better understand the reasons behind these findings. [Extracted from the article]

A study conducted at Shanxi Bethune Hospital aimed to assess the impact of extrathyroidal autoimmune diseases (ADs) on the clinical characteristics and efficacy of iodine-131 (131I) therapy in patients with differentiated thyroid cancer (DTC). The study found that while extrathyroidal ADs may enhance the detection of DTC among elderly women, they have no impact on the clinical characteristics of thyroid cancer or the efficacy of 131I therapy. The presence of ADs may require higher dosages of levothyroxine in patients with DTC. The study suggests that the presence of ADs does not need to be considered when designing treatment plans for patients with DTC. [Extracted from the article]

International Business Machines Corporation (IBM) has been issued a patent for a medication dispenser system that provides exact personal dosing for patients. The system involves obtaining patient information and a list of medications, calculating a personal dose for each medication based on the patient's information, and preparing treatments that contain the personalized doses in a single treatment. This system aims to address issues such as under or over-dosing, handling errors, and limited dosage options for medications. The patent provides a detailed description of the method and system for dispensing medications. [Extracted from the article]

A study conducted by researchers at Charles University in the Czech Republic has found that levothyroxine, a drug used to treat thyroid conditions, can have varying bioavailability depending on the formulation and brand. The researchers used a non-targeted analytical approach to examine different levothyroxine formulations and discovered unexpected compounds, including degradation products and undeclared phospholipids. This study suggests that current quality control mechanisms may not fully capture the complexity of pharmaceutical formulations. The findings highlight the importance of further investigation into the safety and efficacy of thyroid drugs. [Extracted from the article]

A recent study conducted in Bangladesh aimed to fill the knowledge gap regarding primary hypothyroidism in the country. The study included 2,641 adult patients with primary hypothyroidism who had been on levothyroxine (L-T4) replacement therapy for at least 1 year. The study found that only 26.8% of patients had high adherence to L-T4, and nearly half of the patients did not have optimal L-T4 replacement. Factors associated with uncontrolled hypothyroidism included a vegetarian diet, smokeless tobacco use, disease duration over 5 years, consumption of iron or calcium supplements within 4 hours of L-T4 intake, and low or medium adherence to L-T4. The researchers concluded that physicians should address the barriers to reaching the therapeutic goal for these patients. [Extracted from the article]

A new report discusses research findings on female infertility, specifically the relationship between subclinical hypothyroidism (SCH) and perinatal outcomes in singleton pregnancies resulting from assisted reproduction technology (ART). The study found that women with SCH had an increased risk of preterm birth before 34 weeks. However, the use of levothyroxine therapy was found to be a significant protective factor against preterm birth. The researchers suggest that universal screening for thyroid function and appropriate hormone therapy in pregnant women may help reduce perinatal risks, including preterm birth. [Extracted from the article]

A study conducted at the All India Institute of Medical Sciences (AIIMS) aimed to understand the clinical manifestations and outcomes of antithyroid drug therapy (ATD) among patients with Graves' disease in central India. The study found that the prevalence of Graves ophthalmopathy was low, and the rates of remission in response to ATD were also low. Factors such as the grade of goiter, T3 and fT4 levels at diagnosis, and peak carbimazole dose were found to predict non-remission. This research provides valuable insights into the efficacy of ATD therapy for Graves' disease in this specific population. [Extracted from the article]

A study conducted by researchers at Dalian University of Technology in Liaoning, China, has investigated the effects and mechanisms of chemical permeation enhancement (CPE) on the transdermal permeation of levothyroxine sodium (L-T4) patches. The researchers found that the combination of oleic acid (OA) and Azone (NZ) resulted in the best transdermal permeation effect for L-T4. They also discovered that OA improves drug release by increasing the flowability of the pressure-sensitive adhesive (PSA) matrix, and both OA and NZ facilitate L-T4 permeation through the hair follicle pathway. The study concluded that these patches showed a remarkable therapeutic effect on hypothyroidism without causing skin irritation or cytotoxicity. [Extracted from the article]

A recent study conducted by the National Medicines Institute in Warsaw, Poland, explores the challenges and dissatisfaction experienced by patients undergoing levothyroxine replacement therapy for hypothyroidism. The research suggests that the varying response to levothyroxine may be influenced by a complex interplay of individual, environmental, genetic, and epigenetic factors, with immunological disturbances playing a significant role. The study emphasizes the need for a personalized approach to treatment strategies for hypothyroidism. This information provides valuable insights for individuals seeking to understand the causes of difficulties in achieving target thyrotropin levels and persistent symptoms despite hormone replacement therapy. [Extracted from the article]

The article reviews new research from University Hospital on the use of liquid levothyroxine for treating myxoedema coma, highlighting its potential advantages over traditional oral tablets. Topics discussed include the efficacy and bioavailability of liquid levothyroxine, its application in critical care settings, and the need for further research to confirm its benefits and establish treatment protocols.

A recent study conducted at Tsinghua University in Beijing, China, explored the effectiveness of levothyroxine sodium tablets (L-T4) in treating severe complications of hypothyroidism, specifically kidney injury, muscle injury, and lipid metabolism disorders. The study focused on a 52-year-old woman with Hashimoto thyroiditis (HT), a common cause of hypothyroidism. After two months of L-T4 treatment, the patient experienced improvements in kidney function, muscle health, and lipid profile. The study suggests that L-T4 therapy can partially reverse the complications associated with HT and alleviate related symptoms. [Extracted from the article]

The article presents new findings on thyroid drug efficacy from the Children's Hospital of Philadelphia, focusing on the effectiveness of levothyroxine (LT4) monotherapy in pediatric patients after total thyroidectomy. Topics discussed include the variation in triiodothyronine (T3) levels, the comparison of T3 and T4 levels pre- and post-surgery, and the need for further studies to assess the clinical implications of altered T3 levels.

A recent study conducted at the National Research Centre in Egypt has found that co-administering xylo-oligosaccharides (XOS) produced by immobilized Aspergillus terreus xylanase with the drug carbimazole can help mitigate its adverse effects on the adrenal glands. The study showed that XOS not only accelerates the regeneration of adrenal gland cells but also decreases oxidative stress caused by obesity. The immobilized enzyme used in the study demonstrated superior thermal stability and sustained its activity even after multiple cycles and storage. This research provides a potential solution for reducing the harmful effects of carbimazole on the adrenal glands. [Extracted from the article]

A recent study conducted by researchers at Shanghai Jiao Tong University School of Medicine in China explored the effects of low-dose methotrexate (MTX) in combination with methimazole (MMI) on patients with Graves' disease (GD). The study found that the addition of MTX to the treatment regimen resulted in a higher discontinuation rate and a faster improvement in decreased thyrotropin-related antibodies (TRAb) levels compared to treatment with MMI alone. However, there were no significant differences in the levels of free T3, free T4, and TSH between the two groups. The study concluded that supplemental MTX with MMI may be beneficial in the treatment of GD. [Extracted from the article]

A recent study conducted at Maria Curie Sklodowska University in Lublin, Poland compared the catalytic activity of two antithyroid agents, carbimazole and methimazole, on the electroreduction of zinc. The researchers used electrochemical methods to analyze the kinetics and mechanism of zinc electroreduction on a mercury electrode in the presence of these drugs. Molecular dynamics simulations were also performed to understand the effect of the drugs on the hydration sphere of Zn2+ ions. The study found that both carbimazole and methimazole exhibited catalytic abilities, with carbimazole being more effective at lower concentrations and methimazole being more effective at higher concentrations. The presence of both drugs and an increase in the concentration of the supporting electrolyte enhanced the rate of electroreduction. [Extracted from the article]

New research conducted at the University of Porto in Portugal has focused on the therapeutic applications of potassium iodide, particularly its role in shielding the thyroid during radiation emergencies. The ongoing conflict between Ukraine and Russia, as well as concerns about nuclear weapons, have led to a surge in demand for potassium iodide across Europe. The research reviews the current knowledge on the pharmacology, physiology, adverse effects, and protective role of potassium iodide in reducing the risk of thyroid cancer during radiation emergencies. It concludes that while potassium iodide protects the thyroid from radioiodine, it does not affect the absorption of other radioactive materials or defend against external radiation exposure. [Extracted from the article]

Researchers from the University of Sao Paulo in Brazil have conducted a study on the effectiveness of photodynamic inactivation (PDI) against Pseudomonas aeruginosa biofilm. P. aeruginosa is a gram-negative bacterium that is responsible for 7% of hospital-acquired infections and has high mortality rates. The study found that PDI, which involves the use of a photosensitizer and light to produce reactive oxygen species, was effective in reducing the biofilm. The addition of potassium iodide (KI) to the photosensitizer solution further increased the effectiveness of the treatment, resulting in complete eradication of the biofilm. The use of KI in association with a photosensitizer called methylene blue (MB) showed the most promising results. This research provides valuable insights into potential strategies for combating P. aeruginosa infections. [Extracted from the article]

YARAL Pharma Inc. has become the exclusive supplier of authorized generic Levothyroxine Sodium Capsules in the U.S. market. The capsules are used for the treatment of hypothyroidism and as an adjunct therapy for well-differentiated thyroid cancer. It is important to carefully monitor the dosage and potential side effects of the medication, particularly in patients with underlying cardiovascular disease, diabetes mellitus, or adrenal insufficiency. The use of Levothyroxine Sodium Capsules is not recommended for the suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. [Extracted from the article]

A study conducted at Mayo Clinic Arizona has provided new insights into hypersensitivity reactions caused by the drug methimazole (MMI) in patients with Graves disease. The research found that MMI can commonly result in skin allergies, which may lead to discontinuation of therapy. However, the study presented a case of successful treatment using a novel, individualized desensitization protocol that resulted in tolerance of MMI and improvement in thyroid indices. The study suggests that a slower desensitization protocol can be considered for delayed hypersensitivity reactions to MMI, offering an alternative for patients who wish to avoid definitive therapy. [Extracted from the article]

A recent study conducted at Hasbro Children's Hospital in Providence, Rhode Island, has reported on the evaluation and management of methimazole-induced agranulocytosis in pediatric patients with thyrotoxicosis. Agranulocytosis is a rare but serious complication of methimazole use for Graves' disease, and treatment requires discontinuation of methimazole. The study found that prolonged use of saturated solution of potassium iodide (SSKI) was effective in managing thyrotoxicosis in a 17-year-old female patient with methimazole-induced agranulocytosis. The research also highlighted the importance of subspecialty input and intensive evaluation and monitoring in managing agranulocytosis and its associated sequelae. [Extracted from the article]

A recent study conducted at Trakya University in Edirne, Turkey, aimed to evaluate the health-related quality of life in patients with euthyroid Hashimoto's thyroiditis who were undergoing long-term levothyroxine therapy. The study included 44 patients with Hashimoto's thyroiditis and 44 matched controls. The results showed that despite effective control of hypothyroidism, patients with Hashimoto's thyroiditis had lower scores on physical and mental dimensions of the SF-12 scale, indicating a negative impact on their quality of life. The study suggests that comprehensive therapeutic strategies targeting the autoimmune aspects of the disease are necessary for managing Hashimoto's thyroiditis and improving patients' quality of life. [Extracted from the article]

A recent study conducted by researchers at Ahvaz Jundishapur University of Medical Sciences in Iran investigated the effects of levothyroxine replacement therapy on cholesterol levels in hypothyroid patients. The study found that levothyroxine therapy led to a significant reduction in mean thyroid stimulating hormone (TSH), triglycerides, total cholesterol, and low-density lipoprotein (LDL) cholesterol levels. However, there was no significant change in high-density lipoprotein (HDL) cholesterol levels. These findings suggest that levothyroxine therapy has beneficial effects on the lipid profile of patients with overt hypothyroidism, reducing the risk of cardiovascular diseases. [Extracted from the article]

A study conducted by the Division of Urology in Chicago, Illinois, examined the response predictors to radioactive iodine (RAI) therapy in patients with Graves' disease who were pretreated with methimazole. The study found that RAI therapy without using thyroid uptake for dose estimation was effective in treating Graves' disease. The research concluded that further prospective studies are needed to confirm the viability of this simplified and cost-effective approach. [Extracted from the article]

A new report from Shanghai University in China discusses the influence of a combination treatment of propranolol and methimazole on patients with hyperthyroidism. The study compared two groups of patients, one treated with methimazole alone and the other with propranolol plus methimazole. The results showed that the combination treatment was more effective in improving heart rate, thyroid hormone levels, hepatic function, and quality of life, with a lower incidence of adverse reactions. The study also identified AST (aspartate aminotransferase) as an independent risk factor for ineffective treatment. Overall, the findings suggest that propranolol plus methimazole is an effective treatment option for hyperthyroidism. [Extracted from the article]

A recent article in Drug Week discusses new findings on thyroid drugs. The research highlights that thyroid hormones are typically given orally for substitution therapy in patients with hypothyroidism. However, there are some indications for intravenous use of thyroid hormones, such as when oral medications cannot be absorbed properly or in cases of altered consciousness or shock. The article also mentions the use of intravenous levothyroxine in treating myxedema coma and its potential protective effect on the heart in brain-dead organ donors. Overall, the research provides insights into the various applications of thyroid drugs. [Extracted from the article]

A study conducted at Ganzhou People's Hospital focused on the factors that influence postoperative TSH suppression therapy in patients with papillary thyroid carcinoma (PTC). The study included 268 patients who underwent surgery for PTC and received postoperative TSH suppression therapy. The researchers compared various clinical data, laboratory test indicators, medication dosage, and follow-up frequency between patients who achieved the target TSH level and those who did not. The study found that adjusting the dose of levothyroxine sodium in a timely manner during follow-up visits is crucial for optimal thyroid function in PTC patients post-surgery. [Extracted from the article]

A case report from researchers in Guarda, Portugal highlights the rare occurrence of methimazole-induced hepatitis in a 12-year-old boy with hyperthyroidism. Methimazole is commonly used to treat hyperthyroidism due to its low risk of adverse reactions. The patient experienced signs and symptoms of thyrotoxicosis but did not show clinical findings related to liver damage. After discontinuing methimazole treatment and receiving ablative therapy, the patient showed excellent clinical and analytical improvement. The researchers emphasize the importance of monitoring liver enzymes and thyroid function to promptly recognize and prevent unfavorable outcomes. [Extracted from the article]